Proskauer advised Benitec Biopharma on the transaction. Benitec Biopharma (Nasdaq: BNTC), a development-stage, gene therapy-focused, biotechnology company, closed its recent capital raise. The aggregate gross proceeds to Benitec from...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here